Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VNRX Stock Forecast 2025-2026
$0.30
Current Price
$36.84M
Market Cap
Buy 4
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to VNRX Price Targets
+1,566.7%
To High Target of $5.00
+733.3%
To Median Target of $2.50
+233.3%
To Low Target of $1.00
VNRX Price Momentum
-6.3%
1 Week Change
-23.1%
1 Month Change
-52.4%
1 Year Change
-50.0%
Year-to-Date Change
-68.1%
From 52W High of $0.94
+11.1%
From 52W Low of $0.27
📊 TOP ANALYST CALLS
Did VNRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if VolitionRX is one of their latest high-conviction picks.
Latest VNRX Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, VNRX has a bullish consensus with a median price target of $2.50 (ranging from $1.00 to $5.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $0.30, the median forecast implies a 733.3% upside. This outlook is supported by 4 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,566.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VNRX Analyst Ratings
4
Buy
2
Hold
0
Sell
VNRX Price Target Range
Low
$1.00
Average
$2.50
High
$5.00
Current: $0.30
Latest VNRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VNRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 4, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 3, 2025 | Maxim Group | Hold | Downgrade | $N/A | |
| Nov 26, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Nov 17, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $1.50 |
| Sep 30, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Sep 29, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Sep 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Aug 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Jul 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Jul 9, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Jun 10, 2025 | Jones Trading | Justin Walsh | Buy | Initiates | $3.00 |
| Apr 30, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Apr 11, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Apr 8, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $2.50 |
| Apr 1, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 31, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
VolitionRx Limited (VNRX) Competitors
The following stocks are similar to VolitionRX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VolitionRx Limited (VNRX) Financial Data
VolitionRx Limited has a market capitalization of $36.84M with a P/E ratio of -1.0x. The company generates $1.47M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +32.2% quarter-over-quarter, while maintaining an operating margin of -813.2% and return on equity of +103.3%.
Valuation Metrics
Market Cap
$36.84M
Enterprise Value
$44.67M
P/E Ratio
-1.0x
PEG Ratio
0.0x
Price/Sales
26.0x
Growth & Margins
Revenue Growth (YoY)
+32.2%
Gross Margin
N/A
Operating Margin
-813.2%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.7%
Current Ratio
0.1x
Debt/Equity
-0.3x
ROE
+103.3%
ROA
-148.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
VolitionRx Limited (VNRX) Business Model
About VolitionRx Limited
What They Do
Develops blood tests for cancer detection.
Business Model
VolitionRx generates revenue by developing and commercializing innovative blood tests that aid in the early detection of cancer and other diseases. Their Nu.Q platform allows for non-invasive diagnostics, with a focus on partnerships with healthcare institutions to validate and implement their tests in clinical settings.
Additional Information
The company is headquartered in Austin, Texas, and has a significant presence in Belgium. As the demand for precision medicine and early diagnosis grows, VolitionRx's technologies are positioned to play a crucial role in the healthcare sector, potentially improving patient outcomes and driving market adoption.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
75
CEO
Mr. Cameron Reynolds MBA
Country
United States
IPO Year
2012
Website
volition.comVolitionRx Limited (VNRX) Latest News & Analysis
Latest News
Quick Summary
VolitionRx Limited's Nu.Q® NETs H3.1 assay has been included in "DETECSEPS," a study focused on early sepsis detection.
Why It Matters
VolitionRx's inclusion in a key study for early sepsis detection could enhance its market position, drive revenue growth, and attract investor interest in its innovative diagnostic solutions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited (NYSE AMERICAN: VNRX) has made its first sale of Nu.Q® Cancer assays to Hospices Civils de Lyon, a prominent cancer center in France.
Why It Matters
VolitionRx's first sale of Nu.Q® Cancer assays to a top European cancer center signals market validation and potential revenue growth, positively impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited (VNRX) will hold its Q3 2025 earnings call on November 14, 2025, at 8:30 AM EST, featuring key company executives and analysts from various research divisions.
Why It Matters
The upcoming earnings call for VolitionRx Limited provides insights into the company's financial health and strategic direction, crucial for assessing investment potential and market sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited (NYSE: VNRX) will hold a conference call on November 14 at 8:30 a.m. ET to discuss Q3 2025 financial results and business updates.
Why It Matters
The conference call will provide insights into VolitionRx's financial performance and operational strategies, influencing investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
27 days ago
Quick Summary
A conference call is scheduled for November 14 at 8:30 a.m. Eastern Time, taking place in Henderson, Nevada.
Why It Matters
The conference call may provide key insights into company performance, strategic direction, and financial outlook, influencing stock prices and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited (NYSE AMERICAN: VNRX) will participate in the HOPE Animal-Assisted Crisis Response Dogs Annual Conference, supporting its corporate social responsibility initiatives.
Why It Matters
VolitionRx's involvement in the HOPE AACR conference highlights its commitment to corporate social responsibility, potentially enhancing brand reputation and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VNRX Stock
What is VolitionRx Limited's (VNRX) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, VolitionRx Limited (VNRX) has a median price target of $2.50. The highest price target is $5.00 and the lowest is $1.00.
Is VNRX stock a good investment in 2026?
According to current analyst ratings, VNRX has 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VNRX stock?
Wall Street analysts predict VNRX stock could reach $2.50 in the next 12 months. This represents a 733.3% increase from the current price of $0.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is VolitionRx Limited's business model?
VolitionRx generates revenue by developing and commercializing innovative blood tests that aid in the early detection of cancer and other diseases. Their Nu.Q platform allows for non-invasive diagnostics, with a focus on partnerships with healthcare institutions to validate and implement their tests in clinical settings.
What is the highest forecasted price for VNRX VolitionRx Limited?
The highest price target for VNRX is $5.00 from Jason Kolbert at D. Boral Capital, which represents a 1,566.7% increase from the current price of $0.30.
What is the lowest forecasted price for VNRX VolitionRx Limited?
The lowest price target for VNRX is $1.00 from at , which represents a 233.3% increase from the current price of $0.30.
What is the overall VNRX consensus from analysts for VolitionRx Limited?
The overall analyst consensus for VNRX is bullish. Out of 12 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.50.
How accurate are VNRX stock price projections?
Stock price projections, including those for VolitionRx Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 4:39 AM UTC